---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105012"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:30:49.382651+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M

## Summary
- Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.
- Surgical Glaucoma revenue $19.2M (-5% YoY); ordering accounts hit record 1,174, up 4%.
- Dry Eye revenue fell to $0.3M from $1.1M as company focuses on reimbursed TearCare access.
- Adjusted operating expenses $24.4M, down 8% YoY; reaffirmed FY25 guidance of $101-105M.
- Tariff exposure on China products reduced from prior estimate of $3.5-4.5M to $1.0-1.5M for FY25.

## SEC filing metadata
- accession: 0000950170-25-105012
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017025105012/0000950170-25-105012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017025105012/sght-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105012
- JSON: https://secwatch.observer/filing/0000950170-25-105012.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.